Close Menu

ASCO

From changes in trial enrollment to increased flexibility, clinical trials in precision oncology and other fields are feeling the brunt of the ongoing COVID-19 pandemic.

The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.

A roundup of some of the precision oncology-focused research presented at the Gastrointestinal Cancer Symposium in San Francisco, Jan. 23 to 25.

Benefit was seen for patients with high TMB on Keytruda, with ERBB2 amplifications on Perjeta and Herceptin, and with BRAF mutations on Cotellic plus Zelboraf.

At a real-world data workshop, Wendy Rubinstein said that labs have a responsibility under the 21st Century Cures Act to facilitate integration of genomic data into EHRs.

The successful development of new targeted tissue-agnostic cancer drugs will be tied to the use of real-world data and new clinical trial formats.

Despite plenty of hype and some growing pains, artificial intelligence is starting to prove its value in academic and community cancer centers.

Presentations at this month's ASCO meeting demonstrated how efforts are advancing to determine when and how longitudinal ctDNA testing will be useful for oncologists.

Meeting presentations supported tweaking the clinical interpretation of Genomic Health's Oncotype DX and bolstered Biotheranostics' Breast Cancer Index.

Keytruda and Ibrance demonstrate activity in molecularly defined populations, while a new cohort will explore Gilotrif in tumors with NRG1 fusions.

Pages